
Quarterly ResultNov 12, 2026, 04:14 PM
SELLAS Reports Q3 2026 Loss of $10.1M; Awaits Key Clinical Trial Results
AI Summary
SELLAS Life Sciences Group announced its third quarter 2026 financial results, reporting a net loss of $10.1 million ($0.05/share) compared to a $6.8 million loss ($0.06/share) in the prior year. The company ended the quarter with $134.7 million in cash and cash equivalents. Key clinical updates include the upcoming topline results for the Phase 3 REGAL trial of GPS in AML this month, and preliminary topline data for the Phase 2 trial of SLS009 in newly diagnosed AML expected in Q4 2026. The company also presented encouraging Phase 2 data for SLS009 in relapsed/refractory AML at the ASH meeting.
Key Highlights
- SELLAS reported Q3 2026 net loss of $10.1 million, or $0.05 per share, compared to a net loss of $6.8 million, or $0.06 per share, in Q3 2025.
- Cash and cash equivalents stood at $134.7 million as of September 30, 2026.
- Research and development expenses increased to $7.0 million in Q3 2026 from $4.2 million in Q3 2025.
- General and administrative expenses rose to $4.3 million in Q3 2026 from $2.9 million in Q3 2025.
- Phase 3 REGAL trial of Galinpepimut-S (GPS) in AML is nearing topline primary endpoint results this month.
- Preliminary topline data for the Phase 2 trial of SLS009 in newly diagnosed AML is expected in Q4 2026.
- Phase 2 data for SLS009 in relapsed/refractory AML showed a 54% ORR in monocytic AML and 57% ORR in TP53-mutated AML.
Price Impact
More from SLS